David J Bond1, Raymond W Lam, Lakshmi N Yatham. 1. Mood Disorders Centre, University of British Columbia, Room 2C7 - 2255 Wesbrook Mall, Vancouver, BC Canada V6T 2A1.
Abstract
BACKGROUND: Bipolar disorders (BDs) are defined by mania and hypomania, but depressions occur more frequently, last longer, and lead to significant disability. Divalproex is the most frequently prescribed anticonvulsant medication for BD. While some evidence suggests that divalproex prevents depressive episodes during maintenance treatment, it is not commonly used in the treatment of acute depression, and there is a perception that there is little evidence to support its efficacy. METHODS: We conducted a meta-analysis of randomized placebo-controlled trials assessing the efficacy of divalproex in acute BD depression. We searched MEDLINE and the Cochrane Database of Systematic Reviews using the search terms "divalproex AND bipolar depression", "valproate AND bipolar depression", and "valproic acid AND bipolar depression". We also accessed the databases of clinical trial registries, including www.ClinicalTrials.gov, www.who.int/ictrp, http://isrctn.org, http://www.mrw.interscience.wiley.com/cochrane/cochrane_clcentral_articles_fs.html, and www.ClinicalStudyResults.org. All English-language, randomized, double-blind, placebo-controlled trials assessing the efficacy of divalproex monotherapy in the treatment of BD depression were included in the analysis. Data were subjected to meta-analysis to determine the relative risks of response and remission, and combined to estimate average response and remission rates. RESULTS: We identified four trials, with a total sample size of 142 patients. The relative risks of response (RR=2.10, p=0.02) and remission (RR=1.61, p=0.04) were significantly greater for divalproex than placebo. Mean response rates were 39.3% for divalproex and 17.5% for placebo, and mean remission rates were 40.6% and 24.3%, respectively. LIMITATIONS: The total sample size in the four trials was small. CONCLUSIONS: These results provide preliminary evidence that divalproex is efficacious in the treatment of BD depression. Copyright 2009 Elsevier B.V. All rights reserved.
BACKGROUND:Bipolar disorders (BDs) are defined by mania and hypomania, but depressions occur more frequently, last longer, and lead to significant disability. Divalproex is the most frequently prescribed anticonvulsant medication for BD. While some evidence suggests that divalproex prevents depressive episodes during maintenance treatment, it is not commonly used in the treatment of acute depression, and there is a perception that there is little evidence to support its efficacy. METHODS: We conducted a meta-analysis of randomized placebo-controlled trials assessing the efficacy of divalproex in acute BD depression. We searched MEDLINE and the Cochrane Database of Systematic Reviews using the search terms "divalproex AND bipolar depression", "valproate AND bipolar depression", and "valproic acid AND bipolar depression". We also accessed the databases of clinical trial registries, including www.ClinicalTrials.gov, www.who.int/ictrp, http://isrctn.org, http://www.mrw.interscience.wiley.com/cochrane/cochrane_clcentral_articles_fs.html, and www.ClinicalStudyResults.org. All English-language, randomized, double-blind, placebo-controlled trials assessing the efficacy of divalproex monotherapy in the treatment of BD depression were included in the analysis. Data were subjected to meta-analysis to determine the relative risks of response and remission, and combined to estimate average response and remission rates. RESULTS: We identified four trials, with a total sample size of 142 patients. The relative risks of response (RR=2.10, p=0.02) and remission (RR=1.61, p=0.04) were significantly greater for divalproex than placebo. Mean response rates were 39.3% for divalproex and 17.5% for placebo, and mean remission rates were 40.6% and 24.3%, respectively. LIMITATIONS: The total sample size in the four trials was small. CONCLUSIONS: These results provide preliminary evidence that divalproex is efficacious in the treatment of BD depression. Copyright 2009 Elsevier B.V. All rights reserved.
Authors: Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller Journal: Int J Neuropsychopharmacol Date: 2017-02-01 Impact factor: 5.176
Authors: Joseph M Cerimele; Lydia A Chwastiak; Ya-Fen Chan; David A Harrison; Jürgen Unützer Journal: J Gen Intern Med Date: 2013-12 Impact factor: 5.128
Authors: Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk Journal: Bipolar Disord Date: 2018-03-14 Impact factor: 6.744
Authors: Erika F H Saunders; Racha Nazir; Masoud Kamali; Kelly A Ryan; Simon Evans; Scott Langenecker; Alan J Gelenberg; Melvin G McInnis Journal: J Clin Psychiatry Date: 2014-05 Impact factor: 4.384